2.57

2.78% 0.05

Entera Bio Ltd (ENTX)

Overview News Price History Option Chain Financials Discussions Forecast

Entera Bio Ltd stock is traded at $2.57, with a volume of 74,023. It is up +2.78% in the last 24 hours and down -2.26% over the past month. Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Previous Close:

$2.52

Open:

$2.52

24h Volume:

74,023

Relative Volume:

0.53

Market Cap:

$92.82M

Revenue:

$134.00K

Net Income/Loss:

$-9.93M

P/E Ratio:

-7.5588

EPS:

-0.34

Net Cash Flow:

$-6.72M

1W Performance:

+18.26%

1M Performance:

-2.26%

6M Performance:

+54.17%

1Y Performance:

+250.71%

1-Day Range:

$2.41

$2.60

1-Week Range:

$2.00

$2.62

52-Week Range:

$0.71

$3.35

Entera Bio Ltd Stock (ENTX) Company Profile

Name

Entera Bio Ltd

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

972-2-532-7151

Address

KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

ENTX's Discussions on Twitter

Compare ENTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENTX Entera Bio Ltd	2.57	92.82M	134.00K	-9.93M	-6.72M	-0.34
VRTX Vertex Pharmaceuticals Inc	473.06	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	715.00	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	652.00	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.98	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.70	28.75B	3.30B	-501.07M	1.03B	-2.1146

Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-22-21	Initiated	Aegis Capital	Buy

Entera Bio Ltd Stock (ENTX) Latest News

Feb 04, 2025

Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat

Feb 04, 2025

Feb 03, 2025

145,843 Shares in Entera Bio Ltd. (NASDAQ:ENTX) Acquired by Perigon Wealth Management LLC - MarketBeat

Feb 03, 2025

Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 23.1% in January - MarketBeat

Feb 03, 2025

Jan 27, 2025

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Jan 27, 2025

Entera Bio CEO to Present Business Updates at Oppenheimer Healthcare Conference - StockTitan

Jan 27, 2025

Jan 18, 2025

Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decrease in Short Interest - Defense World

Jan 18, 2025

Jan 10, 2025

Entera Bio files Exhibit 5.1 with SEC By Investing.com - Investing.com South Africa

Jan 10, 2025

We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Simply Wall St

Dec 07, 2024

Dec 01, 2024

Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Rises By 19.0% - MarketBeat

Dec 01, 2024

Nov 20, 2024

Knoll Capital Management, LLC's Strategic Acquisition in Entera Bio Ltd - GuruFocus.com

Nov 20, 2024

Nov 17, 2024

Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update - MarketBeat

Nov 17, 2024

Nov 14, 2024

FY2024 EPS Estimate for Entera Bio Decreased by Analyst - MarketBeat

Nov 14, 2024

Nov 11, 2024

HC Wainwright Reaffirms Buy Rating for Entera Bio (NASDAQ:ENTX) - MarketBeat

Nov 11, 2024

Nov 08, 2024